Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Bluejay Diagnostics (NASDAQ: BJDX) boosts cash to advance Symphony IL-6 program

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at stocktitan.net →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Bluejay Diagnostics completed enrollment in its SYMON-II pivotal clinical study with 750 patients and is advancing towards a planned FDA 510(k) submission for its Symphony IL-6 diagnostic test, supported by a new US manufacturing contract and strengthened cash position of approximately $9.6 million.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You can now focus on securing US market access as Bluejay's clinical validation clears a major hurdle and manufacturing risks shrink. Start building pathways to FDA approval and consider US healthcare partnerships now.

◆ Coverage

2 sources · 13 Aug 2026

◆ Related on Wire

◆ Topics

Diagnosticsclinical-trialsfda-510kdiagnosticsmanufacturingcash-raise